Mirxes Holding Co. Ltd. is a biotechnology company specializing in RNA-based technologies, with a core focus on developing diagnostic solutions for the early detection and screening of cancer, cardiovascular, metabolic, and infectious diseases. Headquartered in Singapore and founded in 2014, Mirxes stands out as a pioneer in non-invasive, blood-based microRNA (miRNA) detection, providing products such as GASTROClear for gastric cancer screening and LUNGClear for lung cancer, as well as COVID-19 RT-qPCR test kits. The company’s operations encompass research, development, manufacturing, and commercialization of diagnostic tools and medical devices, serving healthcare providers in key Asian markets including Singapore and China. Mirxes’ business model includes two primary segments: Early Detection and Precision Multi-Omics, which covers the development and supply of diagnostic and life science products, and Infectious Diseases, focusing on test kits and related clinical services. Its mission centers on enabling earlier, actionable disease detection to improve patient outcomes and reduce late-stage diagnoses, reinforcing its role as an innovator in the healthcare diagnostic landscape.